The addition of subcutaneous daratumumab to the standard combination of pomalidomide and dexamethasone (Pd) improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM) during the phase 3 APOLLO trial.
The subcutaneous formulation of daratumumab (Darzalex Faspro, Janssen) was FDA approved in May 2020, but these data provide the first randomized controlled evidence of safety and efficacy in RRMM, according to investigator Meletios A. Dimopoulos, MD, the